Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. to Present at the Gordon Research Conference on Fragile X and Autism-Related Disorders

TEL AVIV, Israel, May 23, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive...
May 15, 2014 07:30 ET | Source: Alcobra Ltd.

Alcobra Announces First Quarter Financial Results and Corporate Update

TEL AVIV, Israel, May 15, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive...
May 12, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. Presents Evidence of Novel Mechanism of Action for Metadoxine Extended Release (MDX) in Cognitive Disorders at the Society of Biological Psychiatry Annual Meeting

-- Improvements in cognitive performance in animal models are consistent with MDX effects in human adults with ADHD – -- Metadoxine has effects on neurotransmitters associated with...
May 08, 2014 12:20 ET | Source: Alcobra Ltd.

Alcobra Announces FDA Clearance of Protocol for Phase IIb Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome

TEL AVIV, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
May 08, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. to Provide Corporate Overview at Oppenheimer and BioMed Conferences

TEL AVIV, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive...
May 07, 2014 16:05 ET | Source: Alcobra Ltd.

Alcobra Ltd. to Release First Quarter 2014 Results and Host Investor Conference Call on Thursday, May 15, 2014

TEL AVIV, Israel, May 7, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive...
May 05, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. Presents Positive Results From Phase IIb Study of Metadoxine Extended Release (MDX) in Adults With Predominantly Inattentive ADHD at APA Annual Meeting

MDX produced statistically significant improvement (p < 0.01) on the primary endpoint compared to placebo MDX was superior to placebo after a single dose while demonstrating a safety...
May 01, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Issued New US Patent Covering Metadoxine Use for Cognitive Disorders

TEL AVIV, Israel, May 1, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug...
April 24, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. to Present New Data for Metadoxine Extended Release (MDX) at Upcoming Meetings

TEL AVIV, Israel, April 24, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive...
April 10, 2014 12:30 ET | Source: Alcobra Ltd.

Alcobra Ltd. Submits Protocol to FDA for Phase IIb Clinical Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome

TEL AVIV, Israel, April 10, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right